Anne Marie Sabrina Wehbe

Array ( [id] => 14993803 [patent_doc_number] => 20190315859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => ANTIBODY AGENTS SPECIFIC FOR HUMAN CD19 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/388508 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14989315 [patent_doc_number] => 20190313615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) [patent_app_type] => utility [patent_app_number] => 16/386901 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16386901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086925 [patent_doc_number] => 20190338273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => METHOD TO OVERCOME DNA CHEMICAL MODIFICATIONS SENSITIVITY OF ENGINEERED TALE DNA BINDING DOMAINS [patent_app_type] => utility [patent_app_number] => 16/379073 [patent_app_country] => US [patent_app_date] => 2019-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16379073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436071 [patent_doc_number] => 20200032219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => HERPES VIRUS STRAINS [patent_app_type] => utility [patent_app_number] => 16/376089 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16376089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824257 [patent_doc_number] => 20210139550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => HINGES 1 AND/OR 4 MODIFIED DYSTROPHINS FOR DYSTROPHINOPATHY THERAPY [patent_app_type] => utility [patent_app_number] => 17/045266 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16760418 [patent_doc_number] => 20210105999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOTOPIC AND HETEROTOPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS [patent_app_type] => utility [patent_app_number] => 17/042767 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16583140 [patent_doc_number] => 20210017542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => AAV6 VARIANTS [patent_app_type] => utility [patent_app_number] => 17/042865 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16760418 [patent_doc_number] => 20210105999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOTOPIC AND HETEROTOPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS [patent_app_type] => utility [patent_app_number] => 17/042767 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16583143 [patent_doc_number] => 20210017545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => TALE-NUCLEASES FOR ALLELE-SPECIFIC CODON MODIFICATION AND MULTIPLEXING [patent_app_type] => utility [patent_app_number] => 17/041359 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628775 [patent_doc_number] => 20210047428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => METHOD FOR GENERATING ANTIBODIES WITH IMPROVED SPECIFICITY AND/OR AFFINITY [patent_app_type] => utility [patent_app_number] => 17/043044 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16614007 [patent_doc_number] => 20210032660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => LIVER TROPIC RECOMBINANT AAV6 VECTORS THAT EVADE NEUTRALIZATION [patent_app_type] => utility [patent_app_number] => 17/042543 [patent_app_country] => US [patent_app_date] => 2019-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16583099 [patent_doc_number] => 20210017501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => MODIFIED ONCOLYTIC ADENOVIRUSES [patent_app_type] => utility [patent_app_number] => 17/040017 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14930527 [patent_doc_number] => 20190300901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => MATERIALS AND METHODS FOR MAKING A RECESSIVE GENE DOMINANT [patent_app_type] => utility [patent_app_number] => 16/290584 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16290584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16168199 [patent_doc_number] => 10709739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-14 [patent_title] => Method for chemoselection [patent_app_type] => utility [patent_app_number] => 16/265546 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10433 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17435936 [patent_doc_number] => 11261248 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-01 [patent_title] => Restricted immunoglobulin heavy chain mice [patent_app_type] => utility [patent_app_number] => 16/265825 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 28429 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 209 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175427 [patent_doc_number] => 20190358305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => AAV-BASED GENE THERAPY FOR GLAUCOMA [patent_app_type] => utility [patent_app_number] => 16/264095 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16264095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175427 [patent_doc_number] => 20190358305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => AAV-BASED GENE THERAPY FOR GLAUCOMA [patent_app_type] => utility [patent_app_number] => 16/264095 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16264095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14225445 [patent_doc_number] => 20190124895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE [patent_app_type] => utility [patent_app_number] => 16/238589 [patent_app_country] => US [patent_app_date] => 2019-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16238589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17135020 [patent_doc_number] => 11136566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Tale-protein scaffolds and uses thereof [patent_app_type] => utility [patent_app_number] => 16/237901 [patent_app_country] => US [patent_app_date] => 2019-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 58 [patent_no_of_words] => 33052 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464789 [patent_doc_number] => 20190184034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => USE OF hM4Di IN THE TREATMENT OF SEIZURE DISORDERS [patent_app_type] => utility [patent_app_number] => 16/227326 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15507 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227326 [rel_patent_id] =>[rel_patent_doc_number] =>)